An investigation for investors in NYSE:STJ shares was announced concerning potential securities laws violations by St. Jude Medical, Inc. and certain of its directors and officers.
Investors who purchased shares of St. Jude Medical, Inc. (NYSE:STJ), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by St. Jude Medical, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On April 28, 2016, Abbott Laboratories announced a definitive agreement to acquire St. Jude Hospitals, Inc. (“St. Jude”), citing St. Jude’s “strong positions in heart failure devices, atrial fibrillation and cardiac rhythm management.” Shares of St. Jude Medical, Inc. (NYSE:STJ) rose to as high as $83.90 per share in August 2016.
Then on October 11, 2016, pre-market, St. Jude Medical, Inc reportedly issued a letter to physicians and patients warning that batteries on thousands of the Company’s implantable defibrillators can quickly and unexpectedly deplete. St. Jude Medical, Inc reportedly stated that two people had died after their devices failed to work correctly because of the drained battery, while 47 others reported dizziness or fainting. The warning applies to devices made before May 2015, which are in use by roughly 350,000 people worldwide. Abbott Laboratories stated that the Company still expects to close its acquisition of St. Jude by the end of this year. Shares of St. Jude Medical, Inc. (NYSE:STJ) declined on October 13, 2106 to $77.75 per share.
Those who purchased NYSE:STJ shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com